Guanidinoacetate–creatine in secondary progressive multiple sclerosis: a case report |
| |
| Authors: | Sergej M. Ostojic Jelena Ostojic Dragana Zanini Tatjana Jezdimirovic Valdemar Stajer |
| |
| Affiliation: | 1.FSPE Applied Bioenergetics Lab, University of Novi Sad, University of Novi Sad, Novi Sad, Serbia;2.Faculty of Health Sciences, University of Pécs, Pécs, Hungary;3.Faculty of Medicine, University of Novi Sad, University of Novi Sad, Novi Sad, Serbia;4.Department of Nutrition and Public Health, University of Agder, Kristiansand, Norway |
| |
| Abstract: | Acute secondary progressive multiple sclerosis (SPMS) is characterized by escalating neurological disability, with limited disease-modifying therapeutic options. A 48-year-old woman with acute SPMS being treated with interferon beta-1a and oral corticosteroids presented as a clinical outpatient with no disease-modifying effects after treatment. A decision was made to treat her with a combination of guanidinoacetate and creatine for 21 days. She had made clinical progress at follow-up, with the intensity of fatigue dropping from severe to mild. Magnetic resonance spectroscopy revealed increased brain choline, creatine, N-acetylaspartate, and glutathione. Patients with SPMS may benefit from guanidinoacetate–creatine treatment in terms of patient- and clinician-reported outcomes; this requires additional study. |
| |
| Keywords: | Multiple sclerosis creatine guanidinoacetic acid brain metabolism case report patient outcome |
|
|
